Literature DB >> 29427103

Spinocerebellar Ataxia Type 2.

Daniel R Scoles1, Stefan M Pulst2.   

Abstract

Spinocerebellar ataxia type 2 (SCA2) is autosomal dominantly inherited and caused by CAG repeat expansion in the ATXN2 gene. Because the CAG repeat expansion is localized to an encoded region of ATXN2, the result is an expanded polyglutamine (polyQ) tract in the ATXN2 protein. SCA2 is characterized by progressive ataxia, and slow saccades. No treatment for SCA2 exists. ATXN2 mutation causes gains of new or toxic functions for the ATXN2 protein, resulting in abnormally slow Purkinje cell (PC) firing frequency and ultimately PC loss. This chapter describes the characteristics of SCA2 patients briefly, and reviews ATXN2 molecular features and progress toward the identification of a treatment for SCA2.

Entities:  

Keywords:  Ataxin-2; Cerebellum; Neurodegeneration; Spinocerebellar ataxia type 2

Mesh:

Substances:

Year:  2018        PMID: 29427103     DOI: 10.1007/978-3-319-71779-1_8

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  16 in total

1.  Antisense Oligonucleotide Therapy for Spinocerebellar Ataxias: Good News for Terrible Diseases.

Authors:  Hélio A G Teive; Carlos Henrique F Camargo; Renato Puppi Munhoz
Journal:  Mov Disord Clin Pract       Date:  2018-05-25

Review 2.  Current Opinions and Consensus for Studying Tremor in Animal Models.

Authors:  Sheng-Han Kuo; Elan D Louis; Phyllis L Faust; Adrian Handforth; Su-Youne Chang; Billur Avlar; Eric J Lang; Ming-Kai Pan; Lauren N Miterko; Amanda M Brown; Roy V Sillitoe; Collin J Anderson; Stefan M Pulst; Martin J Gallagher; Kyle A Lyman; Dane M Chetkovich; Lorraine N Clark; Murni Tio; Eng-King Tan; Rodger J Elble
Journal:  Cerebellum       Date:  2019-12       Impact factor: 3.847

Review 3.  Molecular Mechanisms and Therapeutics for Spinocerebellar Ataxia Type 2.

Authors:  Polina A Egorova; Ilya B Bezprozvanny
Journal:  Neurotherapeutics       Date:  2019-10       Impact factor: 7.620

Review 4.  The protective role of exercise against age-related neurodegeneration.

Authors:  Alyson Sujkowski; Luke Hong; R J Wessells; Sokol V Todi
Journal:  Ageing Res Rev       Date:  2021-12-17       Impact factor: 10.895

Review 5.  Electrophysiological Studies Support Utility of Positive Modulators of SK Channels for the Treatment of Spinocerebellar Ataxia Type 2.

Authors:  Polina A Egorova; Ilya B Bezprozvanny
Journal:  Cerebellum       Date:  2022-01-03       Impact factor: 3.648

Review 6.  Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.

Authors:  C Frank Bennett; Adrian R Krainer; Don W Cleveland
Journal:  Annu Rev Neurosci       Date:  2019-07-08       Impact factor: 12.449

Review 7.  Antisense Drugs Make Sense for Neurological Diseases.

Authors:  C Frank Bennett; Holly B Kordasiewicz; Don W Cleveland
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-10-09       Impact factor: 13.820

8.  In vivo analysis of the spontaneous firing of cerebellar Purkinje cells in awake transgenic mice that model spinocerebellar ataxia type 2.

Authors:  Polina A Egorova; Aleksandra V Gavrilova; Ilya B Bezprozvanny
Journal:  Cell Calcium       Date:  2020-11-16       Impact factor: 6.817

Review 9.  Review of Hereditary and Acquired Rare Choreas.

Authors:  Daniel Martinez-Ramirez; Ruth H Walker; Mayela Rodríguez-Violante; Emilia M Gatto
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2020-08-06

10.  The RNA-binding protein and stress granule component ATAXIN-2 is expressed in mouse and human tissues associated with glaucoma pathogenesis.

Authors:  Chad A Sundberg; Monika Lakk; Sharan Paul; Karla P Figueroa; Daniel R Scoles; Stefan M Pulst; David Križaj
Journal:  J Comp Neurol       Date:  2021-08-18       Impact factor: 3.215

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.